Discounted Cash Flow (DCF) Analysis Levered
Tandem Diabetes Care, Inc. (TNDM)
$26.59
+0.02 (+0.08%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 183.87 | 362.31 | 498.83 | 702.80 | 801.22 | 1,181.04 | 1,740.93 | 2,566.23 | 3,782.78 | 5,576.04 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -8.32 | 41.91 | 24.67 | 111.36 | 50.46 | 80.62 | 118.84 | 175.17 | 258.22 | 380.63 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -2.99 | -19.54 | -32.29 | -23.51 | -34.10 | -49.82 | -73.44 | -108.26 | -159.58 | -235.22 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -11.31 | 22.36 | -7.63 | 87.85 | 16.37 | 30.80 | 45.40 | 66.92 | 98.64 | 145.40 |
Weighted Average Cost Of Capital
Share price | $ 26.59 |
---|---|
Beta | 0.973 |
Diluted Shares Outstanding | 64.15 |
Cost of Debt | |
Tax Rate | -1.88 |
After-tax Cost of Debt | 1.48% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 8.294 |
Total Debt | 419.88 |
Total Equity | 1,705.64 |
Total Capital | 2,125.52 |
Debt Weighting | 19.75 |
Equity Weighting | 80.25 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 183.87 | 362.31 | 498.83 | 702.80 | 801.22 | 1,181.04 | 1,740.93 | 2,566.23 | 3,782.78 | 5,576.04 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -8.32 | 41.91 | 24.67 | 111.36 | 50.46 | 80.62 | 118.84 | 175.17 | 258.22 | 380.63 |
Capital Expenditure | -2.99 | -19.54 | -32.29 | -23.51 | -34.10 | -49.82 | -73.44 | -108.26 | -159.58 | -235.22 |
Free Cash Flow | -11.31 | 22.36 | -7.63 | 87.85 | 16.37 | 30.80 | 45.40 | 66.92 | 98.64 | 145.40 |
WACC | ||||||||||
PV LFCF | 28.80 | 39.69 | 54.70 | 75.39 | 103.91 | |||||
SUM PV LFCF | 302.49 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 6.95 |
Free cash flow (t + 1) | 148.31 |
Terminal Value | 2,996.17 |
Present Value of Terminal Value | 2,141.22 |
Intrinsic Value
Enterprise Value | 2,443.71 |
---|---|
Net Debt | 247.36 |
Equity Value | 2,196.35 |
Shares Outstanding | 64.15 |
Equity Value Per Share | 34.24 |